Share Price and Basic Stock Data
Last Updated: August 29, 2025, 1:23 pm
PEG Ratio | 0.66 |
---|
Quick Insight
Epigral Ltd, operating in the Agro Chemicals/Pesticides industry, currently exhibits a strong financial position with a market capitalization of ₹7,727 Cr. The company's P/E ratio stands at 17.9, indicating a reasonable valuation, while boasting impressive returns with an ROE of 22.3% and ROCE of 24.9%. Furthermore, Epigral Ltd's operational efficiency is evident through an OPM of 27%. With healthy reserves of ₹1,860 Cr and a comfortable ICR of 13.63x, the company appears well-positioned to navigate its borrowings of ₹593 Cr. However, the absence of significant promoter or institutional holdings may pose a governance risk. In conclusion, investors should consider Epigral Ltd's solid financial metrics alongside the potential implications of limited promoter and institutional ownership.
Competitors of Epigral Ltd
Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
---|---|---|---|---|---|---|---|---|---|
Epigral Ltd | 7,885 Cr. | 1,828 | 2,408/1,502 | 18.3 | 441 | 0.34 % | 24.9 % | 22.3 % | 10.0 |
Dharmaj Crop Guard Ltd | 1,221 Cr. | 361 | 391/165 | 23.3 | 117 | 0.00 % | 12.0 % | 9.24 % | 10.0 |
Bhaskar Agrochemicals Ltd | 58.0 Cr. | 111 | 148/55.2 | 10.6 | 34.1 | 0.00 % | 21.3 % | 24.7 % | 10.0 |
Bhagiradha Chemicals & Industries Ltd | 3,394 Cr. | 262 | 416/260 | 119 | 53.9 | 0.06 % | 7.44 % | 4.91 % | 1.00 |
Best Agrolife Ltd | 848 Cr. | 359 | 704/244 | 12.4 | 320 | 0.83 % | 12.9 % | 9.95 % | 10.0 |
Industry Average | 11,873.80 Cr | 1,601.55 | 36.81 | 435.34 | 0.38% | 15.22% | 19.86% | 7.25 |
Quarterly Result
Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 533 | 556 | 538 | 562 | 455 | 478 | 472 | 525 | 651 | 626 | 645 | 628 | 607 |
Expenses | 345 | 375 | 371 | 407 | 360 | 370 | 349 | 369 | 475 | 448 | 463 | 454 | 443 |
Operating Profit | 187 | 180 | 167 | 155 | 95 | 108 | 123 | 155 | 176 | 178 | 183 | 173 | 163 |
OPM % | 35% | 32% | 31% | 28% | 21% | 23% | 26% | 30% | 27% | 28% | 28% | 28% | 27% |
Other Income | 2 | 2 | -0 | 5 | 2 | 1 | 2 | 2 | 2 | 6 | 4 | 3 | 8 |
Interest | 11 | 14 | 21 | 19 | 18 | 21 | 20 | 14 | 14 | 27 | -0 | 12 | 23 |
Depreciation | 22 | 26 | 31 | 30 | 31 | 32 | 31 | 30 | 33 | 32 | 33 | 34 | 42 |
Profit before tax | 156 | 142 | 114 | 110 | 48 | 56 | 74 | 113 | 131 | 124 | 154 | 131 | 107 |
Tax % | 31% | 35% | 33% | 30% | 33% | 32% | 34% | 32% | 34% | 35% | 33% | 34% | -50% |
Net Profit | 108 | 92 | 77 | 77 | 32 | 38 | 49 | 77 | 86 | 81 | 104 | 87 | 160 |
EPS in Rs | 25.94 | 22.04 | 18.58 | 18.48 | 7.62 | 9.18 | 11.87 | 18.45 | 20.70 | 19.38 | 24.00 | 20.08 | 37.18 |
Last Updated: August 19, 2025, 3:47 pm
Below is a detailed analysis of the quarterly data for Epigral Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 607.00 Cr.. The value appears to be declining and may need further review. It has decreased from 628.00 Cr. (Mar 2025) to 607.00 Cr., marking a decrease of 21.00 Cr..
- For Expenses, as of Jun 2025, the value is 443.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 454.00 Cr. (Mar 2025) to 443.00 Cr., marking a decrease of 11.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 163.00 Cr.. The value appears to be declining and may need further review. It has decreased from 173.00 Cr. (Mar 2025) to 163.00 Cr., marking a decrease of 10.00 Cr..
- For OPM %, as of Jun 2025, the value is 27.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Mar 2025) to 27.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 5.00 Cr..
- For Interest, as of Jun 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 11.00 Cr..
- For Depreciation, as of Jun 2025, the value is 42.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.00 Cr. (Mar 2025) to 42.00 Cr., marking an increase of 8.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 107.00 Cr.. The value appears to be declining and may need further review. It has decreased from 131.00 Cr. (Mar 2025) to 107.00 Cr., marking a decrease of 24.00 Cr..
- For Tax %, as of Jun 2025, the value is -50.00%. The value appears to be improving (decreasing) as expected. It has decreased from 34.00% (Mar 2025) to -50.00%, marking a decrease of 84.00%.
- For Net Profit, as of Jun 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 87.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 73.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 37.18. The value appears strong and on an upward trend. It has increased from 20.08 (Mar 2025) to 37.18, marking an increase of 17.10.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 1:34 pm
Metric | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Sales | 394 | 392 | 598 | 710 | 611 | 829 | 1,551 | 2,188 | 1,929 | 2,550 |
Expenses | 245 | 248 | 346 | 405 | 416 | 567 | 1,041 | 1,499 | 1,448 | 1,839 |
Operating Profit | 149 | 144 | 252 | 306 | 194 | 261 | 510 | 689 | 481 | 711 |
OPM % | 38% | 37% | 42% | 43% | 32% | 32% | 33% | 31% | 25% | 28% |
Other Income | 2 | 1 | 8 | 16 | 2 | 2 | 4 | 8 | 6 | 15 |
Interest | 19 | 14 | 9 | 25 | 11 | 29 | 44 | 66 | 73 | 53 |
Depreciation | 44 | 55 | 55 | 54 | 44 | 74 | 86 | 109 | 124 | 133 |
Profit before tax | 88 | 75 | 195 | 242 | 141 | 161 | 383 | 523 | 291 | 540 |
Tax % | 23% | 11% | 20% | 25% | 21% | 37% | 34% | 32% | 33% | 34% |
Net Profit | 67 | 67 | 155 | 183 | 112 | 101 | 253 | 353 | 196 | 357 |
EPS in Rs | 9.49 | 9.40 | 21.97 | 44.38 | 27.19 | 24.48 | 60.84 | 85.04 | 47.12 | 82.68 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 6% | 11% | 7% |
YoY Net Profit Growth
Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 0.00% | 131.34% | 18.06% | -38.80% | -9.82% | 150.50% | 39.53% | -44.48% | 82.14% |
Change in YoY Net Profit Growth (%) | 0.00% | 131.34% | -113.28% | -56.86% | 28.98% | 160.32% | -110.97% | -84.00% | 126.62% |
Epigral Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 33% |
3 Years: | 18% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 26% |
3 Years: | 12% |
TTM: | 72% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 8% |
1 Year: | -4% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 27% |
3 Years: | 25% |
Last Year: | 22% |
Last Updated: Unknown
Balance Sheet
Last Updated: July 25, 2025, 1:21 pm
Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 71 | 71 | 71 | 41 | 42 | 42 | 42 | 42 | 42 | 43 |
Reserves | 224 | 291 | 447 | 241 | 331 | 432 | 684 | 1,028 | 1,213 | 1,860 |
Borrowings | 190 | 123 | 74 | 601 | 737 | 753 | 993 | 879 | 964 | 593 |
Other Liabilities | 55 | 42 | 79 | 162 | 164 | 223 | 405 | 484 | 576 | 655 |
Total Liabilities | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,151 |
Fixed Assets | 364 | 398 | 347 | 295 | 440 | 1,102 | 1,068 | 1,804 | 1,767 | 2,238 |
CWIP | 69 | 3 | 79 | 468 | 691 | 126 | 589 | 158 | 483 | 64 |
Investments | 0 | 29 | 71 | 0 | 0 | 0 | 0 | 21 | 21 | 97 |
Other Assets | 106 | 98 | 173 | 281 | 142 | 221 | 467 | 449 | 524 | 752 |
Total Assets | 540 | 527 | 671 | 1,044 | 1,273 | 1,449 | 2,124 | 2,432 | 2,794 | 3,151 |
Below is a detailed analysis of the balance sheet data for Epigral Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 43.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2024) to 43.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,860.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,213.00 Cr. (Mar 2024) to 1,860.00 Cr., marking an increase of 647.00 Cr..
- For Borrowings, as of Mar 2025, the value is 593.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 964.00 Cr. (Mar 2024) to 593.00 Cr., marking a decrease of 371.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 655.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 576.00 Cr. (Mar 2024) to 655.00 Cr., marking an increase of 79.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 3,151.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,794.00 Cr. (Mar 2024) to 3,151.00 Cr., marking an increase of 357.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 2,238.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,767.00 Cr. (Mar 2024) to 2,238.00 Cr., marking an increase of 471.00 Cr..
- For CWIP, as of Mar 2025, the value is 64.00 Cr.. The value appears to be declining and may need further review. It has decreased from 483.00 Cr. (Mar 2024) to 64.00 Cr., marking a decrease of 419.00 Cr..
- For Investments, as of Mar 2025, the value is 97.00 Cr.. The value appears strong and on an upward trend. It has increased from 21.00 Cr. (Mar 2024) to 97.00 Cr., marking an increase of 76.00 Cr..
- For Other Assets, as of Mar 2025, the value is 752.00 Cr.. The value appears strong and on an upward trend. It has increased from 524.00 Cr. (Mar 2024) to 752.00 Cr., marking an increase of 228.00 Cr..
- For Total Assets, as of Mar 2025, the value is 3,151.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,794.00 Cr. (Mar 2024) to 3,151.00 Cr., marking an increase of 357.00 Cr..
Notably, the Reserves (1,860.00 Cr.) exceed the Borrowings (593.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -41.00 | 21.00 | 178.00 | -295.00 | -543.00 | -492.00 | -483.00 | -190.00 | -483.00 | 118.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 43 | 41 | 47 | 40 | 46 | 52 | 60 | 28 | 34 | 33 |
Inventory Days | 75 | 59 | 45 | 58 | 64 | 51 | 74 | 69 | 90 | 105 |
Days Payable | 31 | 37 | 51 | 52 | 62 | 69 | 42 | 36 | 63 | 50 |
Cash Conversion Cycle | 86 | 63 | 42 | 46 | 48 | 34 | 92 | 61 | 61 | 88 |
Working Capital Days | 43 | 40 | 19 | -27 | -76 | -92 | -26 | -41 | -54 | 26 |
ROCE % | 18% | 37% | 36% | 15% | 16% | 29% | 32% | 17% | 25% |
No valid data available for the Shareholding
This stock is not held by any mutual fund.
Key Financial Ratios
Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
---|---|---|---|---|---|
FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Basic EPS (Rs.) | 84.68 | 47.14 | 85.03 | 60.84 | 24.27 |
Diluted EPS (Rs.) | 84.68 | 47.14 | 85.03 | 60.84 | 24.27 |
Cash EPS (Rs.) | 113.41 | 76.87 | 111.25 | 81.51 | 41.97 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 441.48 | 301.83 | 257.30 | 174.72 | 113.88 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 441.48 | 301.83 | 257.30 | 174.72 | 113.88 |
Revenue From Operations / Share (Rs.) | 591.13 | 464.30 | 526.69 | 373.27 | 199.41 |
PBDIT / Share (Rs.) | 168.27 | 117.39 | 167.73 | 123.61 | 63.42 |
PBIT / Share (Rs.) | 137.54 | 87.66 | 141.51 | 102.93 | 45.72 |
PBT / Share (Rs.) | 125.20 | 69.97 | 125.75 | 92.28 | 38.71 |
Net Profit / Share (Rs.) | 82.68 | 47.13 | 85.03 | 60.84 | 24.27 |
NP After MI And SOA / Share (Rs.) | 82.91 | 47.14 | 85.03 | 60.84 | 24.27 |
PBDIT Margin (%) | 28.46 | 25.28 | 31.84 | 33.11 | 31.80 |
PBIT Margin (%) | 23.26 | 18.87 | 26.86 | 27.57 | 22.92 |
PBT Margin (%) | 21.17 | 15.06 | 23.87 | 24.72 | 19.41 |
Net Profit Margin (%) | 13.98 | 10.15 | 16.14 | 16.29 | 12.16 |
NP After MI And SOA Margin (%) | 14.02 | 10.15 | 16.14 | 16.29 | 12.16 |
Return on Networth / Equity (%) | 18.78 | 15.61 | 33.04 | 34.82 | 21.30 |
Return on Capital Employeed (%) | 22.30 | 18.07 | 32.94 | 26.87 | 17.92 |
Return On Assets (%) | 11.34 | 7.00 | 14.52 | 11.90 | 6.96 |
Long Term Debt / Equity (X) | 0.23 | 0.39 | 0.40 | 1.06 | 0.71 |
Total Debt / Equity (X) | 0.30 | 0.72 | 0.71 | 1.36 | 0.87 |
Asset Turnover Ratio (%) | 0.85 | 0.73 | 0.96 | 0.86 | 0.00 |
Current Ratio (X) | 1.57 | 0.64 | 0.64 | 0.83 | 0.46 |
Quick Ratio (X) | 0.78 | 0.30 | 0.32 | 0.55 | 0.32 |
Inventory Turnover Ratio (X) | 4.06 | 4.51 | 6.62 | 7.30 | 0.00 |
Dividend Payout Ratio (NP) (%) | 0.00 | 5.30 | 2.94 | 0.00 | 0.00 |
Dividend Payout Ratio (CP) (%) | 0.00 | 3.25 | 2.24 | 0.00 | 0.00 |
Earning Retention Ratio (%) | 0.00 | 94.70 | 97.06 | 0.00 | 0.00 |
Cash Earning Retention Ratio (%) | 0.00 | 96.75 | 97.76 | 0.00 | 0.00 |
Interest Coverage Ratio (X) | 13.63 | 6.64 | 10.64 | 11.60 | 9.05 |
Interest Coverage Ratio (Post Tax) (X) | 7.70 | 3.66 | 6.39 | 6.71 | 4.46 |
Enterprise Value (Cr.) | 8753.81 | 5509.59 | 4780.47 | 5010.23 | 0.00 |
EV / Net Operating Revenue (X) | 3.43 | 2.86 | 2.18 | 3.23 | 0.00 |
EV / EBITDA (X) | 12.06 | 11.30 | 6.86 | 9.76 | 0.00 |
MarketCap / Net Operating Revenue (X) | 3.21 | 2.36 | 1.79 | 2.61 | 0.00 |
Retention Ratios (%) | 0.00 | 94.69 | 97.05 | 0.00 | 0.00 |
Price / BV (X) | 4.30 | 3.63 | 3.67 | 5.57 | 0.00 |
Price / Net Operating Revenue (X) | 3.21 | 2.36 | 1.79 | 2.61 | 0.00 |
EarningsYield | 0.04 | 0.04 | 0.09 | 0.06 | 0.00 |
After reviewing the key financial ratios for Epigral Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
- For Diluted EPS (Rs.), as of Mar 25, the value is 84.68. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 84.68, marking an increase of 37.54.
- For Cash EPS (Rs.), as of Mar 25, the value is 113.41. This value is within the healthy range. It has increased from 76.87 (Mar 24) to 113.41, marking an increase of 36.54.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 441.48. It has increased from 301.83 (Mar 24) to 441.48, marking an increase of 139.65.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 591.13. It has increased from 464.30 (Mar 24) to 591.13, marking an increase of 126.83.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 168.27. This value is within the healthy range. It has increased from 117.39 (Mar 24) to 168.27, marking an increase of 50.88.
- For PBIT / Share (Rs.), as of Mar 25, the value is 137.54. This value is within the healthy range. It has increased from 87.66 (Mar 24) to 137.54, marking an increase of 49.88.
- For PBT / Share (Rs.), as of Mar 25, the value is 125.20. This value is within the healthy range. It has increased from 69.97 (Mar 24) to 125.20, marking an increase of 55.23.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 82.68. This value is within the healthy range. It has increased from 47.13 (Mar 24) to 82.68, marking an increase of 35.55.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 82.91. This value is within the healthy range. It has increased from 47.14 (Mar 24) to 82.91, marking an increase of 35.77.
- For PBDIT Margin (%), as of Mar 25, the value is 28.46. This value is within the healthy range. It has increased from 25.28 (Mar 24) to 28.46, marking an increase of 3.18.
- For PBIT Margin (%), as of Mar 25, the value is 23.26. This value exceeds the healthy maximum of 20. It has increased from 18.87 (Mar 24) to 23.26, marking an increase of 4.39.
- For PBT Margin (%), as of Mar 25, the value is 21.17. This value is within the healthy range. It has increased from 15.06 (Mar 24) to 21.17, marking an increase of 6.11.
- For Net Profit Margin (%), as of Mar 25, the value is 13.98. This value exceeds the healthy maximum of 10. It has increased from 10.15 (Mar 24) to 13.98, marking an increase of 3.83.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.02. This value is within the healthy range. It has increased from 10.15 (Mar 24) to 14.02, marking an increase of 3.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 18.78. This value is within the healthy range. It has increased from 15.61 (Mar 24) to 18.78, marking an increase of 3.17.
- For Return on Capital Employeed (%), as of Mar 25, the value is 22.30. This value is within the healthy range. It has increased from 18.07 (Mar 24) to 22.30, marking an increase of 4.23.
- For Return On Assets (%), as of Mar 25, the value is 11.34. This value is within the healthy range. It has increased from 7.00 (Mar 24) to 11.34, marking an increase of 4.34.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.39 (Mar 24) to 0.23, marking a decrease of 0.16.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.72 (Mar 24) to 0.30, marking a decrease of 0.42.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. It has increased from 0.73 (Mar 24) to 0.85, marking an increase of 0.12.
- For Current Ratio (X), as of Mar 25, the value is 1.57. This value is within the healthy range. It has increased from 0.64 (Mar 24) to 1.57, marking an increase of 0.93.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has increased from 0.30 (Mar 24) to 0.78, marking an increase of 0.48.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.06. This value is within the healthy range. It has decreased from 4.51 (Mar 24) to 4.06, marking a decrease of 0.45.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 5.30 (Mar 24) to 0.00, marking a decrease of 5.30.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 3.25 (Mar 24) to 0.00, marking a decrease of 3.25.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 94.70 (Mar 24) to 0.00, marking a decrease of 94.70.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 96.75 (Mar 24) to 0.00, marking a decrease of 96.75.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 13.63. This value is within the healthy range. It has increased from 6.64 (Mar 24) to 13.63, marking an increase of 6.99.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.70. This value is within the healthy range. It has increased from 3.66 (Mar 24) to 7.70, marking an increase of 4.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,753.81. It has increased from 5,509.59 (Mar 24) to 8,753.81, marking an increase of 3,244.22.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.43. This value exceeds the healthy maximum of 3. It has increased from 2.86 (Mar 24) to 3.43, marking an increase of 0.57.
- For EV / EBITDA (X), as of Mar 25, the value is 12.06. This value is within the healthy range. It has increased from 11.30 (Mar 24) to 12.06, marking an increase of 0.76.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 94.69 (Mar 24) to 0.00, marking a decrease of 94.69.
- For Price / BV (X), as of Mar 25, the value is 4.30. This value exceeds the healthy maximum of 3. It has increased from 3.63 (Mar 24) to 4.30, marking an increase of 0.67.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.21. This value exceeds the healthy maximum of 3. It has increased from 2.36 (Mar 24) to 3.21, marking an increase of 0.85.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Epigral Ltd:
- Net Profit Margin: 13.98%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 22.3% (Industry Average ROCE: 15.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.78% (Industry Average ROE: 19.86%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.3 (Industry average Stock P/E: 36.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.98%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Agro Chemicals/Pesticides | �Epigral Tower�, Behind Safal Profitaire, Ahmedabad Gujarat 380015 | helpdesk@epigral.com http://www.epigral.com |
Management | |
---|---|
Name | Position Held |
Mr. Maulik Patel | Chairman & Managing Director |
Mr. Kaushal Soparkar | Executive Director |
Mr. Ankit Patel | Non Exe.Non Ind.Director |
Mr. Karana Patel | Non Exe.Non Ind.Director |
Mr. Darshan Patel | Non Exe.Non Ind.Director |
Mr. Manubhai Patel | Independent Director |
Mr. Sanjay Asher | Independent Director |
Mr. Kanubhai Patel | Independent Director |
Mr. Raju Swamy | Independent Director |
Ms. Priyanka Chopra | Independent Woman Director |
FAQ
What is the intrinsic value of Epigral Ltd?
Epigral Ltd's intrinsic value (as of 29 August 2025) is 1444.64 which is 20.97% lower the current market price of ₹1,828.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹7,885 Cr. market cap, FY2025-2026 high/low of 2,408/1,502, reserves of ₹1,860 Cr, and liabilities of 3,151 Cr.
What is the Market Cap of Epigral Ltd?
The Market Cap of Epigral Ltd is 7,885 Cr..
What is the current Stock Price of Epigral Ltd as on 29 August 2025?
The current stock price of Epigral Ltd as on 29 August 2025 is 1,828.
What is the High / Low of Epigral Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Epigral Ltd stocks is 2,408/1,502.
What is the Stock P/E of Epigral Ltd?
The Stock P/E of Epigral Ltd is 18.3.
What is the Book Value of Epigral Ltd?
The Book Value of Epigral Ltd is 441.
What is the Dividend Yield of Epigral Ltd?
The Dividend Yield of Epigral Ltd is 0.34 %.
What is the ROCE of Epigral Ltd?
The ROCE of Epigral Ltd is 24.9 %.
What is the ROE of Epigral Ltd?
The ROE of Epigral Ltd is 22.3 %.
What is the Face Value of Epigral Ltd?
The Face Value of Epigral Ltd is 10.0.